Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors

Rheumatology

Volumn 38, Issue SUPPL. 2, 1999, Pages 14-18

  Furst, D E ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Doxycydine; Efficacy; Leflunomide; Metalloproteinase inhibitors; Minocycline; Mycophenolate mofetil; Pharmacokinetics; Rheumatoid arthritis; Toxicity

Indexed keywords

ANTIRHEUMATIC AGENT; DIHYDROOROTATE DEHYDROGENASE; GUANINE NUCLEOTIDE; INOSINATE DEHYDROGENASE; INTERLEUKIN 2; LEFLUNOMIDE; MATRIX METALLOPROTEINASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TRANSFORMING GROWTH FACTOR ALPHA;

ALOPECIA; ANTIBODY PRODUCTION; BONE MARROW SUPPRESSION; CHOLESTASIS; CONFERENCE PAPER; DNA SYNTHESIS; ENZYME INHIBITION; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL TOXICITY; LIVER TOXICITY; NATURAL KILLER CELL; PANCREATITIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS INFECTION; WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBIOTICS, ANTINEOPLASTIC; ARTHRITIS, RHEUMATOID; ENZYME INHIBITORS; HUMANS; ISOXAZOLES; METALLOENDOPEPTIDASES; MYCOPHENOLIC ACID;

EID: 0032692178     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.suppl_1.14     Document Type: Conference Paper

References (26)

1. Bartlett RR, Zielinski T, Ulrich Schorlemmer H et al. Leflunomide: a novel immunomodulating drug. In: Lewis AJ, Furst DE, eds. Non-steroidal anti-inflammatory drugs. New York: Marcel Dekker, 1994:349-66.
2. Silva Junior HT, Morris RE. Leflunomide and malononitrilamides. Am J Med Sci 1997;313:289-301.
3. Furst DE. Leflunomide and nitrogen mustard. Baillière's Clin Rheumatol 1995;9:711-29.
4. Weber W, Harnisch L. Use of a population pharmacokinetic model to predict clinical outcome of leflunomide, a new DMARD in the treatment of rheumatoid arthritis. [Abstract] Arthritis Rheum 1997;40(suppl.):S153.
5. Mladenovic VZ, Domlijan BB, Rozman I et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38:1595-603.
6. Weaver A, Caldwell J, Alsen N, Cohen S for the Leflunomide RA Investigator Group, Strand V. Treatment of active RA with leflunomide compared to placebo or MTX. [Abstract] Arthritis Rheum 1998;41(suppl.):S1316.
7. Furst D, Cannon GW, Fox R for the Leflunomide RA Investigator Group. Onset of effect and duration of response to leflunomide treatment of active RA compared to placebo or methotrexate. [Abstract] Arthritis Rheum 1998;41(suppl.):S155.
8. Smolen JS, Kalden JR, Rozman B, Scott DL, Leon-Fredrich I, Rosenberg R for the Leflunomide RA Investigator Group. A double-blind, randomized, phase III trial of leflunomide vs. placebo vs. sulfasalazine in RA. [Abstract] Arthritis Rheum 1998;41(suppl.):S131.
9. Schiff M, Kaine J for the Leflunomide RA Investigator Group, Sharp J, Strand V. X-ray analysis of 12 months treatment of active RA with leflunomide compared to placebo or methotrexate. [Abstract] Arthritis Rheum 1998; 41(suppl.):S131.
10. Weinblatt M, Kremer JM, Coblyn JS et al. Leflunomide plus methotrexate in refractory rheumatoid arthritis: a pilot study. [Abstract] Arthritis Rheum 1997;40(suppl.):S193.
11. Bullingham RE, Nicholls A, Gale M. Pharmacokinetics of mycophenolate mofetil: a short review. Transplant Proc 1996;28:925-9.
12. Ransom DT. Mechanism of action of mycophenolate mofetil. Ther Drug Monitoring 1995,17:681-4.
13. Barre J, Simon N, Tillement JP. Mycophenolate mofetil, a new immunosuppressive agent: is pharmacokinetic monitoring justified? Therapie 1997;52:139-42.
14. Schiff MH, Stein G, Leishman B. Cellcept (mycophenolate mofetil-MMF); a new treatment for RA: a 9-month, randomized, double-blind trial comparing 1g BID and 2g BID. [Abstract] Arthritis Rheum 1997;40:S194.
15. Schiff MH, Goldblum R, Rees MMC. New DMARD, mycophenolate mofetil (Myco-M), effectively treats refractory rheumatoid arthritis (RA) patients for one year. [Abstract] Arthritis Rheum 1990;34(suppl.):S89.
16. Hamdy H, McKendry RJR, Mierins E et al. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a twenty-four week controlled clinical trial. Arthritis Rheum 1987;30:361-8.
17. Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Sys Farm 1997;54:285-94.
18. Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis. Arthritis Rheum 1994;37:1115-26.
19. Shlopov BV, Smith GN Jr, Hasty KA. The effect of doxycycline treatment on collagenase production by osteoarthritic chondrocytes, [Abstract] Arthritis Rheum 1997;40(suppl.):S88.
20. Kloppenburg M, Mattie H, Donwes N et al. Minocycline in the treatment of RA: relationship of serum concentrations in efficacy. J Rheumatol 1995;22:611-6.
21. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988;15:355-66.
22. Kloppenburg M, Breedveld FC, Terweil JP et al. Minocycline in active RA: a double-blind, placebo-controlled trial. Arthritis Rheum 1994;37:629-36.
23. Tilley BC, Alarcon GS, Heyse SP et al. Minocycline in RA: a 48 week double-blind, placebo-controlled trial. Ann Intern Med 1995; 122:81-9.
24. O'Dell JR, Haire CE, Palmer W et al. Treatment of early RA with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1997;40:842-8.
25. Knights SE, Leandro MJ, Khamashta MA et al. Minocycline induced lupus. [Abstract] Arthritis Rheum 1997;40(suppl.):S107.
26. Physician's desk reference, 52nd edn. Montvale, NJ: Medical Economics Co., 1997.